miércoles, 21 de agosto de 2013

CDC Hepatitis Updates - Surveillance for Viral Hepatitis - U.S., 2011

CDC Hepatitis Updates - Surveillance for Viral Hepatitis - U.S., 2011

CDC Hepatitis Updates - Surveillance for Viral Hepatitis - U.S., 2011

Viral Hepatitis Updates from CDC
Surveillance for Viral Hepatitis – United States, 2011As part of CDC’s National Notifiable Disease Surveillance System (NNDSS), viral hepatitis case-reports are received electronically from state health departments via CDC’s National Electronic Telecommunications System for Surveillance (NETSS). Although surveillance infrastructure is in place for reporting of acute infection, reports of chronic hepatitis B and C, which account for the greatest burden of disease, are not submitted by all states. Surveillance capacity to monitor both acute and chronic viral hepatitis is limited at the state and local levels, resulting in underreporting and incomplete variable quality data that is insufficient for understanding the magnitude of viral hepatitis. Data in this report should be interpreted with the consideration that reported cases of acute or chronic viral hepatitis represent only those relatively few infected persons who were detected, diagnosed, met a stringent case definition, and eventually reported to CDC in 2011. Because most acute and chronic infections are not reported, this Summary is mainly useful in detecting major trends in viral hepatitis A (HAV), B (HBV) and C (HCV).

MMWR: Locations and Reasons for Initial Testing for Hepatitis C Infection — Chronic Hepatitis Cohort Study, United States, 2006–2010
Chronic hepatitis C virus (HCV) infection causes substantial morbidity and mortality in the United States. Testing and treatment of asymptomatic persons might avert progression to more advanced disease. To better understand where and why persons with chronic HCV infection sought their initial testing, 2006–2010 data were analyzed from a survey conducted as part of the ongoing Chronic Hepatitis Cohort Study. Of 4,689 patients with HCV infection who responded to the survey, 60.4% reported that their initial HCV test occurred in a physician's office. CDC's risk-based indications (e.g., injection drug use and hemodialysis) were cited by 1,045 (22.3%) of the patients as reasons for testing, whereas clinical indications (e.g., abnormal liver function tests or liver-related symptoms such as jaundice) were cited by 2,121 (45.2%), suggesting that many HCV infections were identified only after the patient had become symptomatic. Promoting U. S. Preventive Services Task Force and CDC recommendations for testing and identifying strategies that help physicians implement HCV testing in their offices might help facilitate timely identification of HCV infection and reduce morbidity and mortality.http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6232a3.htm

Give Birth to end of Hep B: Protect newborns - Administer hepatitis B vaccine at birth
The Immunization Action Coalition (IAC) is urging hospitals and birthing centers to meet the national standard of care by providing a universal birth dose of hepatitis B vaccine.

Medscape CDC Expert Commentary - Testing for Hepatitis C: New Guidance Features Chong-Gee Teo, MD, PhD, Laboratory Branch Chief in the Division of Viral Hepatitis at CDC. Dr. Teo discusses CDC’s updated guidance for clinicians and laboratorians for testing for hepatitis C virus (HCV) infection. If you do not have a Medscape account, you will need to provide your name, email address and profession to sign up.   http://www.medscape.com/viewarticle/808327

No hay comentarios:

Publicar un comentario